177 related articles for article (PubMed ID: 7538713)
21. [Effects of transurethral catheterization on uroflow rate in the pressure-flow study of patients with benign prostatic hyperplasia].
Zhao SC; Zheng SB; Tan WL; Mao XM; Zhang P; Huang ZM; Zhang HJ; Zuo Y
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):710-2. PubMed ID: 17918710
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
23. [Contribution of pressure-flow relationship studies in the evaluation of benign hypertrophy of the prostate].
Haab F
Prog Urol; 1999 Feb; 9(1):151-5. PubMed ID: 10212970
[TBL] [Abstract][Full Text] [Related]
24. Correlations between parameters in pressure-flow analysis and histological compositions in prostate in patients with benign prostatic hyperplasia.
Ichiyanagi O; Nakada T
Urol Int; 1997; 59(3):154-60. PubMed ID: 9428431
[TBL] [Abstract][Full Text] [Related]
25. Re: Bladder outflow tract obstruction and urinary retention from benign prostatic hypertrophy treated by balloon dilatation.
Klein L
Br J Urol; 1990 Oct; 66(4):443. PubMed ID: 1699630
[No Abstract] [Full Text] [Related]
26. Influence of bladder outlet obstruction and detrusor contractility on residual urine in patients with benign prostatic hyperplasia.
Zhang P; Wu Z; Gao J
Chin Med J (Engl); 2003 Oct; 116(10):1508-10. PubMed ID: 14570611
[TBL] [Abstract][Full Text] [Related]
27. Clinical considerations of obstructed bladder neck.
Brosig W
Prog Clin Biol Res; 1976; 6():23-9. PubMed ID: 66690
[No Abstract] [Full Text] [Related]
28. [Benign prostatic syndrome (BPS)].
Neubauer S
MMW Fortschr Med; 2010 Jun; 152(23):37-40. PubMed ID: 20608463
[No Abstract] [Full Text] [Related]
29. Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.
Witjes WP; de Wildt MJ; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
J Urol; 1996 Sep; 156(3):1026-34. PubMed ID: 8709301
[TBL] [Abstract][Full Text] [Related]
30. Prostatic Artery Embolization for the Treatment of Benign Prostatic Hyperplasia in the Setting of Bladder Calculi.
Kim JI; Brader R; Viprakasit DP; Isaacson AJ
J Vasc Interv Radiol; 2017 Feb; 28(2):306-308. PubMed ID: 28110763
[No Abstract] [Full Text] [Related]
31. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up.
Hamann MF; Naumann CM; Seif C; van der Horst C; Jünemann KP; Braun PM
Eur Urol; 2008 Oct; 54(4):902-7. PubMed ID: 18502565
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of residual urine volume in bladder outlet obstruction with benign prostatic hyperplasia].
Wu Z; Wu K; Wang B
Zhonghua Wai Ke Za Zhi; 1997 Jun; 35(6):374-6. PubMed ID: 10374477
[TBL] [Abstract][Full Text] [Related]
33. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?
Rigatti L; Naspro R; Salonia A; Centemero A; Ghezzi M; Guazzoni G; Briganti A; Rigatti P; Montorsi F
Urology; 2006 Jun; 67(6):1193-8. PubMed ID: 16750253
[TBL] [Abstract][Full Text] [Related]
34. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.
Oelke M; Baard J; Wijkstra H; de la Rosette JJ; Jonas U; Höfner K
Eur Urol; 2008 Aug; 54(2):419-26. PubMed ID: 18325657
[TBL] [Abstract][Full Text] [Related]
35. Detrusor instability as an energy-saving device in prostatic obstruction.
Cucchi A; Achilli MP; Ravasi S; Arrigoni N
J Urol; 1997 Mar; 157(3):866-70. PubMed ID: 9072588
[TBL] [Abstract][Full Text] [Related]
36. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
[TBL] [Abstract][Full Text] [Related]
37. [Benign prostatic hyperplasia. Therapeutic possibilities].
Pannek J; Haupt G; Schulze H
Med Monatsschr Pharm; 1994 Aug; 17(8):237-46. PubMed ID: 7523841
[No Abstract] [Full Text] [Related]
38. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
Parsons JK
J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
[TBL] [Abstract][Full Text] [Related]
39. Intraprostatic temperature monitoring during transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia.
Wagrell L; Schelin S; Bolmsjö M; Brudin L
J Urol; 1998 May; 159(5):1583-7. PubMed ID: 9554359
[TBL] [Abstract][Full Text] [Related]
40. Hugh Hampton Young, benign prostatic hyperplasia, and "the cure of prostatic obstruction".
Parsons JK; Partin AW
J Am Coll Surg; 2005 Nov; 201(5):654-5. PubMed ID: 16256905
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
